title: p95HER2 and breast cancer.
abstract: A subtype of HER2-positive tumors with distinct biological and clinical features expresses a series of carboxy-terminal fragments collectively known as p95HER2. One of these fragments, named 100- to 115-kDa p95HER2 or 611-CTF, is hyperactive because of its ability to form homodimers maintained by intermolecular disulfide bonds. Despite lacking the majority of the extracellular domain, this HER2 fragment drives breast cancer progression in vivo. The recent availability of specific anti-p95 antibodies has confirmed previous results indicating that the expression of p95HER2 is predictive of poor prognosis and correlates with resistance to the treatment with trastuzumab, a therapeutic antibody directed against the extracellular domain of HER2.
authors.affiliation: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. jarribas@vhio.net
authors.forename: Joaquín
authors.initials: J
authors.lastname: Arribas
authors.forename: José
authors.initials: J
authors.lastname: Baselga
authors.forename: Kim
authors.initials: K
authors.lastname: Pedersen
authors.forename: Josep Lluís
authors.initials: JL
authors.lastname: Parra-Palau
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D017434:Protein Structure, Tertiary; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases